Plexium is advancing developments in targeted protein degradation (TPD). By using their proprietary ultra-high-throughput cell-based (uHTS) screening technology, Plexium is detecting and designing monovalent protein degraders that can be used in many modalities. The assay directly measures degradation of multiple target proteins in disease-relevant environments to identify hit compounds. The uHTS screening is part of the larger Plexium Platform that combines genomic analysis, computational modeling and AI analytics to create their TPD drugs.The monovalent protein degraders overcome the limitations of current approaches and include the discovery of novel E3 ligases and new molecular glues. Plexium is creating a diverse pipeline that is currently in preclinical stages.

<p>Plexium is advancing developments in targeted protein degradation (TPD). By using their proprietary ultra-high-throughput cell-based (uHTS) screening technology, Plexium is detecting and designing monovalent protein degraders that can be used in many modalities. The assay directly measures degradation of multiple target proteins in disease-relevant environments to identify hit compounds. The uHTS screening is part of the larger Plexium Platform that combines genomic analysis, computational modeling and AI analytics to create their TPD drugs.The monovalent protein degraders overcome the limitations of current approaches and include the discovery of novel E3 ligases and new molecular glues. Plexium is creating a diverse pipeline that is currently in preclinical stages.</p>


Plexium

Drug notes:

About:

Jobs: